SYDNEY, AUSTRALIA – 6 March 2019 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”. The data will be presented at the World Immunotherapy Congress 2019 in San Diego USA, by Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer at 3:00 PM Pacific Standard Time on 5th March 2019.
SYDNEY, AUSTRALIA – 6 March 2019 - Immutep Limited (ASX: IMM;...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.5¢ | 31.5¢ | $465.8K | 1.452M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 587491 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 18585 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
